Regenerative Stem Cell Therapy for Stroke in Europe

NCT02849613 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2021-10-06

No results posted yet for this study

Summary

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life.

Conditions

Interventions

OTHER

Adipose Derived Stem Cells

OTHER

Vehicle media

Sponsors & Collaborators

  • Horizon 2020 - European Commission

    collaborator OTHER
  • University Grenoble Alps

    collaborator OTHER
  • Servicio Madrileño de Salud, Madrid, Spain

    collaborator OTHER
  • St. Anne's University Hospital Brno, Czech Republic

    collaborator OTHER
  • Andaluz Health Service

    collaborator OTHER_GOV
  • University of Glasgow

    collaborator OTHER
  • University of Eastern Finland

    collaborator OTHER
  • Etablissement Français du Sang

    collaborator OTHER
  • Tampere University

    collaborator OTHER
  • Histocell SL, Spain

    collaborator UNKNOWN
  • Oy Medfiles Ltd

    collaborator INDUSTRY
  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV
  • Hospices Civils de Lyon

    collaborator OTHER
  • Association Groupe ESSEC

    collaborator OTHER
  • NOVADISCOVERY SAS, France

    collaborator UNKNOWN
  • Finovatis

    collaborator OTHER
  • Centre Hospitalier Universitaire de Besancon

    collaborator OTHER
  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER
  • University Hospital, Toulouse

    collaborator OTHER
  • University Hospital, Bordeaux

    collaborator OTHER
  • University Hospital, Caen

    collaborator OTHER
  • Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

    collaborator OTHER
  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    collaborator OTHER
  • Servicio de Salud de Castilla La Mancha, Albacete, Spain

    collaborator UNKNOWN
  • Servicio Gallego de Salud

    collaborator OTHER_GOV
  • Pirkanmaa Hospital District, Tampere, Finland

    collaborator UNKNOWN
  • Hospital Vall d'Hebron

    collaborator OTHER
  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

    collaborator OTHER
  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Olivier DETANTE, MD PhD · University Hospital Grenoble-Alpes, France

  • Exuperio DIEZ TEJEDOR, MD PhD · La Paz University Hospital, Madrid, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02849613 on ClinicalTrials.gov